- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Glenmark Pharma makes entry into U.S. semisolid product market
Mumbai, India - Glenmark Pharmaceuticals, Inc., has begun U.S. marketing and distribution of five Clobetasol Propionate dermatology products, The Economy Times reports.
Mumbai, India
- A subsidiary of Glenmark Pharmaceuticals, Glenmark Pharmaceuticals, Inc., has begun marketing and distributing five Clobetasol Propionate dermatology products in the U.S., The Economy Times reports.
The products include cream, E-cream, ointment gel and topical solution and are being handled through a U.S.-based pharmaceutical development company, according to The Times.
The company plans to launch another 11 products throughout the course of a year.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
